Milrinone Wockhardt Uk

Milrinone, the active ingredient in Milrinone Wockhardt Uk, is a phosphodiesterase‑3 inhibitor presented as an injectable solution for intravenous use. It treats acute decompensated heart failure, cardiogenic shock and low cardiac output syndrome in hospitalized patients.

GNH USA supplies Milrinone Wockhardt Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide.

Milrinone is a phosphodiesterase‑3 inhibitor used in the management of severe cardiac conditions.

- Acute decompensated heart failure: improves cardiac output and reduces systemic vascular resistance. - Cardiogenic shock: provides inotropic support to maintain blood pressure and organ perfusion. - Low cardiac output syndrome: enhances myocardial contractility to increase systemic circulation.

Milrinone may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Hypotension: transient drop in blood pressure. - Arrhythmias: including premature ventricular contractions. - Flushing: warmth and redness of skin.

Serious or Rare Side Effects: - Severe hypotension: sustained low blood pressure requiring intervention. - Life‑threatening ventricular arrhythmias: torsades de pointes or ventricular tachycardia. - Myocardial ischemia: chest pain due to reduced coronary perfusion. - Thrombocytopenia: significant drop in platelet count. - Anaphylactic reaction: rare hypersensitivity with airway compromise.

When using Milrinone, clinicians should observe specific precautions to minimize risks.

- Cardiac monitoring: continuous ECG and hemodynamic assessment are required. - Blood pressure: monitor for hypotension, especially during initiation or dose changes. - Electrolyte balance: correct hypokalemia and hypomagnesemia before infusion. - Concomitant vasodilators: use with caution as additive blood pressure effects may occur. - Pregnancy: category B, use only if potential benefit justifies potential risk to fetus. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase milrinone plasma levels and risk of toxicity. - Concurrent use with other potent vasodilators (e.g., nitroglycerin): can cause severe hypotension.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the inotropic response, requiring dose adjustment. - Diuretics: may exacerbate electrolyte disturbances, increasing arrhythmia risk. - Anticoagulants: monitor for bleeding as milrinone may affect platelet function.